TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia

• TP53 mutations in the absence of 17p-deletion correlate with rapid disease progression and poor survival in chronic lymphocytic leukemia (CLL). Herein, we determined the TP53 mutation frequency in 268 newly diagnosed CLL patients from a population-based material. Overall, we detected TP53 mutations in 3.7% of patients (n= 10), where 7/10 cases showed a concomitant 17p-deletion, confirming the high prevalence of TP53 mutation in 17p-deleted patients. Only 3 (1.1%) of the newly diagnosed patients in our cohort thereby carried TP53 mutations without 17p-deletion, a frequency that is much lower than previous reports on referral cohorts (3-6%). Our findings imply that TP53 mutations are rare at CLL onset and instead may arise during disease progression.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Chronic lymphocytic leukemia

TP53 mutation

17p-deletion

overall survival

time to treatment

MEDICINE

MEDICIN

Medical Genetics

Medicinsk genetik

Molekylär genetik

Molecular Genetics

Molecular Biology

Molekylärbiologi

TP53 mutation

17p-deletion

Prognosis

Chronic lymphocytic leukemia

Publication and Content Type

ref (subject category)

art (subject category)